{"url_path":"/sec/apvo/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-221661-index.html","accession_number":"0001193125-26-221661","cik":"0001671584","ticker":"APVO","issuer_name":"Aptevo Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1671584/0001193125-26-221661-index.html","primary_entity_key":"0001671584","primary_entity_name":"Aptevo Therapeutics Inc."},"word_count":68,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\nIn the quarter ended March 31, 2026, none of the Company's directors or executive officers adopted, terminated or materially modified a plan for the purchase or sale of its securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or a non-Rule 10b5-1 trading arrangement for the purchase or sale of its securities, within the meaning of Item 408 of Regulation S-K.\n\n \n\n54"}